Skip to content
Peptide research

DSIP

Also known as Delta Sleep-Inducing Peptide
Category
Specialized Research
Administration routes
Injectable
Regulatory status
Not FDA-approved

A synthetic nine-amino-acid peptide marketed to promote deep, delta-wave sleep, with secondary claims for stress, pain, and hormone balance. The evidence is thin: small human studies suggest a modest sleep benefit, while the other uses rest on animal and mechanism data. There is no long-term clinical safety data, and, unusually, no receptor or gene for it has been identified. Not an approved drug in the US, and most supply is unregulated research-grade.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring peptide made of nine amino acids, first isolated in 1977 from the brain blood of rabbits during induced sleep. Initially believed to promote deep (delta wave) sleep, decades of research have revealed a much broader biological profile that includes stress reduction, pain relief, anti-addiction effects, and hormone regulation. Despite extensive study, DSIP remains somewhat mysterious — its gene, specific receptor, and precursor protein have never been identified. It has been detected in human breast milk and various brain regions, and it breaks down very quickly in the bloodstream (about 15 minutes), suggesting the body stabilizes it through binding to carrier proteins.

How it works in the body

DSIP's mechanism remains unresolved, and no specific receptor has been established. Proposed sleep and neuroendocrine effects do not establish a direct GABA-A receptor mechanism or reliable promotion of deep sleep in humans.

Research overview

DSIP research spans nearly five decades since its 1977 discovery. The peptide interacts with NMDA receptors (involved in learning and memory) and influences stress hormones through a protein related to the body's cortisol regulation system. Sleep studies have produced mixed results: some trials show improved sleep quality and faster sleep onset in people with insomnia, while others show minimal benefit. Stress protection is supported mainly by preclinical work; human pain and withdrawal findings remain preliminary. A comprehensive 2006 review concluded that DSIP remains "a still unresolved riddle," noting that a DSIP-like substance rather than DSIP itself may be responsible for many observed effects. A clinical preparation called Deltaran has been used in Russia, particularly for children with nervous system problems after chemotherapy. Recent 2024 research has explored engineered DSIP variants capable of crossing the blood-brain barrier, showing effectiveness in mouse models of insomnia.

Who researches DSIP?

Commonly researched by

  • People researching cognitive enhancement

    Studied for neuroprotective effects, memory, or cognitive performance.

  • People exploring sleep quality improvement

    Researched for effects on sleep architecture, circadian rhythm, or sleep quality.

  • People researching longevity and anti-aging interventions

    Studied for effects on aging pathways, cellular health, or lifespan extension.

  • People exploring pain management options

    Researched for analgesic or pain-modulating properties.

  • People researching experimental oncology peptides

    Studied for effects on cancer cell targeting or tumor biology in preclinical research.

Important considerations for

  • Those with Epilepsy

    Moderate

    DSIP modulates GABA and sleep-wake neurotransmission. May interact unpredictably with seizure thresholds.

  • Those who are pregnant or breastfeeding

    Absolute

    No safety data.

Safety & interactions

Do not use if

  • Epilepsy

    Moderate

    DSIP modulates GABA and sleep-wake neurotransmission. May interact unpredictably with seizure thresholds.

General cautions

  • Pregnancy

    Absolute

    No safety data.

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(6)

Rated by level of concern

  • Long-term safety has not been established in any clinical research study

    High

    Multiple 2024-2026 reviews noting absence of long-term safety data; no registered controlled long-term trials

  • Very short in vitro half-life (~15 minutes) raises bioavailability questions

    Low

    PMID 6548966 (Schoenenberger 1984); ScienceDirect 0196-9781(87)90031-3 (degradation/aggregation of DSIP in plasma/serum)

  • No identified gene, receptor, or precursor protein; mechanism incompletely understood

    Moderate

    Kovalzon 2006, J Neurochem 'DSIP: a still unresolved riddle' (doi:10.1111/j.1471-4159.2006.03693.x)

  • Headaches, dizziness, GI issues reported anecdotally

    Low

    Community reviews (anecdotal); controlled sleep studies reported no daytime side effects

  • Fatigue or excessive lethargy if dose too high or timing wrong

    Low

    Mechanistic (sleep-promoting effect); anecdotal user reports

  • Injection site reactions including redness and mild irritation

    Low

    General subcutaneous peptide-injection experience (no DSIP-specific controlled data)

Interaction summary(6)

Rated by direction with this peptide

  • Benzodiazepines and Z-drug hypnotics (e.g., zolpidem)

    CautionTheoretical

    Additive CNS depression/sedation is plausible when combined with a sleep- and delta-wave-promoting peptide, but there are no formal human interaction studies.

    Mechanism-based (DSIP sleep-promoting effect); no direct interaction data

  • Alcohol (ethanol)

    CautionTheoretical

    Concurrent use with active intoxication could add to CNS depression; notably, DSIP itself has been studied to relieve alcohol-withdrawal symptoms, so the concern is combined sedation, not withdrawal.

    PMID 6328354; PMID 9617990 (alcohol withdrawal series)

  • Opioid analgesics / opioid withdrawal

    ProtectiveLow

    Open-label human series report DSIP rapidly reduces opioid withdrawal symptoms, likely via indirect met-enkephalin release (the protective effect). Caution: concurrent opioid analgesia could be additive on sedation/CNS depression, so monitor.

    PMID 6328354; PMID 9617990

  • Growth hormone secretagogues (GHRH, GHRP-6/ipamorelin)

    SynergisticTheoretical

    Rodent studies show DSIP stimulates GHRH/GH release and inhibits somatostatin, so an additive GH-releasing effect is conceivable, but this is demonstrated only in animals.

    Iyer & McCann 1987, Peptides (GH release in rat)

  • Corticosteroids / HPA-axis modulators

    CautionTheoretical

    DSIP may lower basal ACTH/cortisol and blunt stress-induced HPA activation in some studies, so a theoretical interaction with glucocorticoid dynamics exists, though human data are conflicting.

    PMID 2554357 (ACTH reduction); PMID 7777652 (no effect)

  • Other CNS depressants / general anesthetics

    CautionTheoretical

    Additive sedation is plausible; DSIP has historically been explored as an anesthetic-sparing/adjunct agent, underscoring overlapping CNS-depressant activity.

    European Journal of Anaesthesiology 2001 (DSIP review to exist); mechanism-based

Known risks(11)

  • Long-term safety has not been established in any clinical research study

  • Very short in vitro half-life (~15 minutes) raises questions about bioavailability and effective dosing

  • No identified gene, receptor, or precursor protein — mechanism of action remains incompletely understood

  • Headaches, dizziness, and gastrointestinal issues (nausea, stomach pain) reported anecdotally

  • Fatigue or excessive lethargy if dose is too high or timing is incorrect

  • Injection site reactions including redness and mild irritation

  • Potential for downstream hormonal shifts due to DSIP influence on LH, GH, and cortisol release

  • When used as an isoflurane adjunct in anesthesia, DSIP unexpectedly increased heart rate and reduced anesthesia depth — contraindicated during general anesthesia

  • May complicate substance use disorder treatment given interaction with opioid receptor systems

  • No large-scale human safety or toxicology studies have been conducted

  • Quality varies significantly among unregulated products sold online — contamination and purity concerns

Drug interactions(6)

  • Opioid analgesics

    DSIP acts antagonistically on opiate receptors and may alter the efficacy or effects of opioid medications. This interaction was therapeutically exploited in addiction treatment studies.

  • Benzodiazepines and sedative-hypnotics

    Potential additive sedation when combined with sleep-promoting medications. No formal interaction studies have been conducted.

  • Isoflurane and general anesthetics

    Clinical evidence shows DSIP increased heart rate and reduced anesthesia depth when used as an isoflurane adjunct. DSIP should be discontinued prior to planned general anesthesia.

  • Corticosteroids

    DSIP decreases basal corticotropin levels and blocks its release, and shows homology to glucocorticoid-induced leucine zipper (GILZ). May interact with glucocorticoid signaling pathways.

  • Growth hormone and somatostatin analogs

    DSIP stimulates GH secretion and inhibits somatostatin. May interfere with somatostatin analog therapies (e.g., octreotide) or alter GH-related treatment protocols.

  • Alcohol

    DSIP demonstrated ability to inhibit alcohol dependence development in 87% of alcohol-dependent patients. May alter alcohol metabolism or subjective effects.

Research & benefits

Evidence base

Evidence Level
Preliminary
Total Studies
30
Human Studies
8

Clinical evidence for DSIP spans several small human trials (typically 7-16 subjects) conducted primarily in the 1980s-1990s, with contradictory results for sleep promotion. Withdrawal and pain findings are also preliminary, relying largely on uncontrolled studies. No large-scale randomized controlled trials have been conducted. The peptide's gene, receptor, and precursor remain unidentified, limiting mechanistic understanding.

Researched for(7)

Rated by confidence in the evidence

  • Sleep quality improvement

    Medium

    A small double-blind trial found modestly shorter sleep latency, though effects were weak and unreplicated.

    PMID 3583493 (efficacy in chronic insomniacs, short-term); Karger Neuropsychobiology 26(4):193, 1992 (double-blind, placebo-controlled); Kaeser 1984, PMID 6391926 (open-label; sleep normalized in 6 of 7 patients)

  • Stress response modulation

    Low

    Animal data suggest HPA-axis calming, but human results are mixed with no clinical trial.

    PMID 2554357 (ACTH reduction in man); PMID 7777652 (no effect on CRH/meal-induced ACTH-cortisol)

  • Pain reduction

    Low

    Strong rodent painkilling data, but human evidence is one small uncontrolled 1984 pilot.

    PMID 2853064 (antinociception in mice); 1984 open-label chronic-pain pilot (primary source; uncontrolled, n=7)

  • Anti-addiction support

    Low

    Uncontrolled case series report rapid easing of opioid and alcohol withdrawal, without placebo controls.

    PMID 6328354 (withdrawal symptom treatment); PMID 9617990 (Backmund et al.)

  • Endocrine regulation

    Low

    Rodent studies show shifts in growth hormone and LH, but human endocrine data stay sparse.

    PMID 3575154 (LH elevation in rats); Iyer & McCann 1987, Peptides (GH release in rat, hypothalamic/pituitary)

  • Potential anti-tumor and anti-aging effects

    Speculative

    Based on a single mouse research line showing fewer tumors and longer lifespan, no human data.

    PMID 12782416 (Popovich et al., Mech Ageing Dev 2003, mouse geroprotection/tumor incidence)

  • Neuroprotective effects

    Low

    Rodent studies show stroke recovery and antioxidant CNS effects, with no human trials yet.

    PMC8434407 (motor recovery after focal stroke in rats); PMID 12668217 (mitochondrial/antioxidant effects)

Benefits(7)

  • Sleep quality improvement

    Double-blind study in 16 chronic insomniacs showed higher sleep efficiency and shorter sleep latency vs placebo (Bes et al., 1992). Open trial in 7 severe insomniacs showed sleep normalization lasting 3-7 months (Kaeser, 1984).

  • Stress response modulation

    Functions as a stress-limiting factor with protective effects under hypoxic conditions. Decreases basal corticotropin levels and blocks its release.

  • Pain reduction

    Pilot study in 7 chronic pain patients showed significant pain reduction in 6 of 7 subjects with concurrent improvement in depressive symptoms (Larbig et al., 1984). Potent antinociceptive effect demonstrated in mice via intracerebroventricular administration.

  • Anti-addiction support

    Clinical data showed 97% of opiate-dependent and 87% of alcohol-dependent patients experienced symptom alleviation. Animal studies suggest indirect opioid-system activation rather than direct opioid-receptor antagonism.

  • Endocrine regulation

    Stimulates luteinizing hormone (LH) and growth hormone (GH) secretion while inhibiting somatostatin. May normalize blood pressure and myocardial contraction.

  • Potential anti-tumor and anti-aging effects

    Mouse study showed DSIP decreased total spontaneous tumor incidence 2.6-fold, increased maximum lifespan by 24.1%, and reduced chromosome aberrations by 22.6%.

  • Neuroprotective effects

    Research demonstrated DSIP recovers motor function in SD rats after focal stroke (2021, Molecules journal). Post-chemotherapy administration in children reduced bioelectrical brain impairment in 9 of 10 subjects.

Key studies(7)

  1. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study

    Double-blind randomized controlled trial165 nights (3 treatment nights)

    Bes F, Hofman W, Schuur J, Van Boxtel C

    Neuropsychobiology

    1992

    Higher sleep efficiency and shorter sleep latency with DSIP vs placebo, but effects were modest. Subjective sleep quality did not improve. Authors concluded short-term DSIP treatment is not likely to be of major therapeutic benefit for chronic insomnia.

  2. Kovalzon VM, Strekalova TV

    Journal of Neurochemistry

    2006

    Comprehensive review concluding that DSIP remains poorly understood. Hypothesizes a DSIP-like peptide rather than DSIP itself may be responsible for observed biological activity. Notes lack of identified DSIP gene, protein, and receptor.

  3. A clinical trial with DSIP

    Open-label clinical trial710 injection series with 3-7 month follow-up

    Kaeser HE

    European Neurology

    1984

    In 6 of 7 severe insomnia patients, sleep was normalized for follow-up periods of 3-7 months after a series of 10 DSIP injections. Daytime mood and performance also improved.

  4. Larbig W, Gerber WD, Kluck M, Schoenenberger GA

    European Neurology

    1984

    DSIP significantly lowered pain levels in 6 of 7 chronic pain patients (migraine, vasomotor headaches, chronic tinnitus, psychogenic pain). Concurrent significant reduction in depressive symptoms observed.

  5. Schneider-Helmert D, Schoenenberger GA

    International Journal of Clinical Pharmacology, Therapeutics and Toxicology

    1981

    Sleep increased by 59% within 130 minutes after DSIP treatment vs placebo. Delayed effects included shorter sleep onset latency and improved sleep efficiency on subsequent nights.

  6. Multiple authors

    Molecules (MDPI)

    2021

    DSIP demonstrated neuroprotective effects and facilitated motor function recovery in Sprague-Dawley rats following focal stroke.

  7. Multiple authors

    Frontiers in Pharmacology

    2024

    DSIP fusion peptides secreted by Pichia pastoris successfully crossed the blood-brain barrier and demonstrated efficacy in treating insomnia in PCPA-induced mouse models, representing a novel delivery approach.

What research suggests over time

  • Hours-Days

    Small human trials

    Acute IV infusion (1980s-90s small trials, n=7-16): modest improvements in sleep latency and efficiency reported, but contradictory results across studies.

  • Weeks 2-4

    Small human trial

    Series of 10 IV DSIP infusions normalized sleep in 6 of 7 severe insomnia patients in one study (Eur Neurol 1984).

  • Long-term

    Preliminary

    Sleep normalization sustained 3-7 months in the same cohort; mechanism remains poorly understood (J Neurochem 2006). No modern Phase 3 trials.

Regulation & availability

Why researchers look at it

Small human trials showed improved sleep quality in chronic insomniacs with effects persisting months after treatment ended, and one mouse study demonstrated both lifespan extension and reduced tumor rates. Despite nearly five decades of research, DSIP's gene, receptor, and precursor protein have never been identified — making it one of the most enigmatic bioactive peptides known. Engineered 2024 variants capable of crossing the blood-brain barrier may finally crack the mechanism.

Estimated cost
No approved product and no verified reference price
FDA status
DSIP is not FDA-approved and is not eligible for compounding: it is not on FDA's list of bulk substances pharmacies may use. FDA's Pharmacy Compounding Advisory Committee reviewed it (as emideltide) in July 2026: trade press reported a committee vote; FDA has not posted minutes or changed the list. Its safety statement concerns the proposed administration route, rather than all historical human exposure. DSIP (emideltide) is not covered by the draft interim compounding policy HHS posted on October 28, 2026, which names BPC-157, epitalon, KPV, MOTS-c, semax and TB-500.
WADA status
DSIP is not currently listed on the World Anti-Doping Agency (WADA) Prohibited List as a specifically named substance. However, its ability to stimulate growth hormone (GH) and luteinizing hormone (LH) secretion means it could potentially fall under the category of GH-releasing peptides or substances with anti-doping implications. Athletes should exercise caution and consult with sports medicine professionals, as WADA's prohibited list includes broad categories that could encompass DSIP's pharmacological effects.
Prescribability
DSIP is not FDA-approved and is not eligible for compounding: it is not on FDA's list of bulk substances pharmacies may use. FDA's Pharmacy Compounding Advisory Committee reviewed it (as emideltide) in July 2026: trade press reported a committee vote; FDA has not posted minutes or changed the list.
Availability
DSIP is not FDA-approved and has no approved US pharmaceutical product. Some clinics advertise it, but a prescription does not establish lawful compounding eligibility. No routine 503A or 503B bulk-compounding basis was identified. Deltaran has documented Russian registration; its current registry validity requires confirmation.

International status

  • EU

    Not approved

  • US

    DSIP is not FDA-approved and is not eligible for compounding: it is not on FDA's list of bulk substances pharmacies may use. FDA's Pharmacy Compounding Advisory Committee reviewed it (as emideltide) in July 2026: trade press reported a committee vote; FDA has not posted minutes or changed the list.

  • Russia

    Deltaran has documented Russian drug registration, LP-003849 dated September 20, 2016.

Regulatory timeline(7)

  1. 1977
    DSIP first isolated and characterized by Schoenenberger-Monnier group in Basel, Switzerland
  2. 1983
    First clinical trials published — sleep studies, chronic pain, and addiction treatment (European Neurology)
  3. 1992
    Double-blind RCT by Bes et al. published in Neuropsychobiology — modest sleep effects, concluded not major therapeutic benefit
  4. 2001
    Pollard and Pomfrett publish a DSIP review in European Journal of Anaesthesiology. The human isoflurane trial reporting increased heart rate and lighter anesthesia was published in 2009.
  5. 2006
    Kovalzon and Strekalova publish comprehensive review in Journal of Neurochemistry calling DSIP 'a still unresolved riddle'
  6. 2021
    MDPI Molecules publishes study showing DSIP recovers motor function in rats after focal stroke — neuroprotective applications explored
  7. 2024
    Frontiers in Pharmacology publishes DSIP fusion peptide study using Pichia pastoris secretion system for blood-brain barrier crossing

Sources & FAQs

Research sources(8)

  1. PubMed (National Library of Medicine) — primary clinical studies and reviews
  2. Frontiers in Pharmacology — 2024 DSIP fusion peptide BBB crossing study
  3. Molecules (MDPI) — 2021 stroke recovery animal study
  4. European Journal of Anaesthesiology — DSIP and anesthesia review (2001)
  5. ScienceDirect — biochemistry and molecular biology overview
  6. Wikipedia — comprehensive DSIP pharmacology summary with citations
  7. Neuropsychobiology — 1992 double-blind insomnia trial
  8. European Neurology — 1984 clinical trials (insomnia and chronic pain)

Frequently asked questions(6)

What is DSIP and how was it discovered?

DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring nonapeptide first isolated in 1977 by Swiss researchers from the cerebral venous blood of rabbits during induced sleep. Its amino acid sequence is Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu with a molecular weight of approximately 850 daltons.

Does DSIP actually improve sleep?

Results are mixed. Some clinical studies showed modest improvements in sleep efficiency and latency in insomniacs, and one small trial found sleep normalization lasting 3-7 months. However, a well-designed double-blind study concluded that short-term DSIP treatment is 'not likely to be of major therapeutic benefit' for chronic insomnia. Subjective sleep quality often did not improve.

What other effects does DSIP have beyond sleep?

DSIP has a remarkably broad biological profile including stress modulation, pain reduction (analgesic effects in 6/7 chronic pain patients), anti-addiction effects (97% of opiate-dependent patients showed symptom alleviation), endocrine regulation (stimulates LH and GH, inhibits somatostatin), neuroprotection, and potential anti-tumor properties.

Why is DSIP called an 'unresolved riddle'?

Despite nearly 50 years of research, the DSIP gene has never been located, no specific receptor has been identified, and its precursor protein is unknown. A 2006 review suggested that a DSIP-like peptide, rather than DSIP itself, may be responsible for many observed biological activities.

How is DSIP typically administered?

In clinical studies, DSIP was typically administered intravenously. In the wellness/peptide therapy space it is given by subcutaneous injection, though this use lacks robust clinical validation.

Is DSIP safe for long-term use?

Long-term safety has not been established in clinical studies. Short-term clinical trials reported no significant adverse effects, but these studies were small and brief. FDA has evaluated DSIP safety for compounding and identified unresolved safety concerns. Reported side effects from anecdotal use include headaches, dizziness, nausea, and injection site reactions.